Kimberly Peterson1, Eric Dieperink2, Johanna Anderson3, Erin Boundy3, Lauren Ferguson3, Mark Helfand3. 1. Evidence-based Synthesis Program (ESP) Coordinating Center, VA Portland Health Care System, Department of Veterans Affairs, 3710 SW U.S. Veterans Hospital Road, Mail Code: R&D 71, Portland, OR, 97239, USA. Kimberly.Peterson4@va.gov. 2. Mental/Behavioral Health, Minneapolis VA Health Care System, Department of Veterans Affairs, Minneapolis, MN, USA. 3. Evidence-based Synthesis Program (ESP) Coordinating Center, VA Portland Health Care System, Department of Veterans Affairs, 3710 SW U.S. Veterans Hospital Road, Mail Code: R&D 71, Portland, OR, 97239, USA.
Abstract
OBJECTIVE: This study aims to conduct an evidence review of the effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment for major depressive disorder. METHODS: We searched MEDLINE®, the Cochrane Central Registry of Controlled Trials, and PsycINFO through February 2017. We used prespecified criteria to select studies, abstract data, and rate internal validity and strength of the evidence (PROSPERO number CRD42016036358). RESULTS: We included two randomized trials (RCT), five controlled cohort studies, and six modeling studies of mostly women in their mid-40s with few comorbidities. CNSDose (ABCB1, ABCC1, CYP2C19, CYP2D6, UGT1A1) is the only pharmacogenomics test that significantly improved remission (one additional remitting patient in 12 weeks per three genotyped, 95% CI 1.7 to 3.5) and reduced intolerability in an RCT. ABCB1 genotyping leads to one additional remitting patient in 5 weeks per three genotyped (95% CI 3 to 20), but tolerability was not reported. In an RCT, GeneSight (CYP2D6, CYPC19, CYP1A2, SLC6A4, HTR2A) did not statistically significantly improve remission, and evidence is inconclusive about its tolerability. Evidence is generally low strength because RCTs were few and underpowered. Cost-effectiveness is unclear due to lack of directly observed cost-effectiveness outcomes. We found no studies that evaluated whether pharmacogenomics shortens time to optimal treatment, whether improvements were due to switches to genetically congruent medication, or whether effectiveness varies based on test and patient characteristics. CONCLUSIONS: Certain pharmacogenomics tools show promise of improving short-term remission rates in women in their mid-40s with few comorbidities. But, important evidence limitations preclude recommending their widespread use and indicate a need for further research.
OBJECTIVE: This study aims to conduct an evidence review of the effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment for major depressive disorder. METHODS: We searched MEDLINE®, the Cochrane Central Registry of Controlled Trials, and PsycINFO through February 2017. We used prespecified criteria to select studies, abstract data, and rate internal validity and strength of the evidence (PROSPERO number CRD42016036358). RESULTS: We included two randomized trials (RCT), five controlled cohort studies, and six modeling studies of mostly women in their mid-40s with few comorbidities. CNSDose (ABCB1, ABCC1, CYP2C19, CYP2D6, UGT1A1) is the only pharmacogenomics test that significantly improved remission (one additional remitting patient in 12 weeks per three genotyped, 95% CI 1.7 to 3.5) and reduced intolerability in an RCT. ABCB1 genotyping leads to one additional remitting patient in 5 weeks per three genotyped (95% CI 3 to 20), but tolerability was not reported. In an RCT, GeneSight (CYP2D6, CYPC19, CYP1A2, SLC6A4, HTR2A) did not statistically significantly improve remission, and evidence is inconclusive about its tolerability. Evidence is generally low strength because RCTs were few and underpowered. Cost-effectiveness is unclear due to lack of directly observed cost-effectiveness outcomes. We found no studies that evaluated whether pharmacogenomics shortens time to optimal treatment, whether improvements were due to switches to genetically congruent medication, or whether effectiveness varies based on test and patient characteristics. CONCLUSIONS: Certain pharmacogenomics tools show promise of improving short-term remission rates in women in their mid-40s with few comorbidities. But, important evidence limitations preclude recommending their widespread use and indicate a need for further research.
Entities:
Keywords:
Antidepressant treatment; Major depressive disorder; Pharmacogenomics; Systematic review
Authors: Alessio Squassina; Mirko Manchia; Vangelis G Manolopoulos; Mehmet Artac; Christina Lappa-Manakou; Sophia Karkabouna; Konstantinos Mitropoulos; Maria Del Zompo; George P Patrinos Journal: Pharmacogenomics Date: 2010-08 Impact factor: 2.533
Authors: Michael Bauer; Andrea Pfennig; Emanuel Severus; Peter C Whybrow; Jules Angst; Hans-Jürgen Möller Journal: World J Biol Psychiatry Date: 2013-07-03 Impact factor: 4.132
Authors: Elizabeth J J Berm; Margot de Looff; Bob Wilffert; Cornelis Boersma; Lieven Annemans; Stefan Vegter; Job F M van Boven; Maarten J Postma Journal: PLoS One Date: 2016-01-11 Impact factor: 3.240
Authors: Lindsay S Elliott; John C Henderson; Moni B Neradilek; Nicolas A Moyer; Kristine C Ashcraft; Ranjit K Thirumaran Journal: PLoS One Date: 2017-02-02 Impact factor: 3.240
Authors: Laura M Hack; Gabriel R Fries; Harris A Eyre; Chad A Bousman; Ajeet B Singh; Joao Quevedo; Vineeth P John; Bernhard T Baune; Boadie W Dunlop Journal: J Affect Disord Date: 2019-02-06 Impact factor: 4.839
Authors: Katarina Arandjelovic; Harris A Eyre; Eric Lenze; Ajeet B Singh; Michael Berk; Chad Bousman Journal: J Neural Transm (Vienna) Date: 2017-10-29 Impact factor: 3.575
Authors: Ryan Abbott; Donald D Chang; Harris A Eyre; Chad A Bousman; David A Merrill; Helen Lavretsky Journal: Am J Geriatr Psychiatry Date: 2017-05-25 Impact factor: 4.105
Authors: Lorena Carrascal-Laso; Manuel Ángel Franco-Martín; Elena Marcos-Vadillo; Ignacio Ramos-Gallego; Belén García-Berrocal; Eduardo Mayor-Toranzo; Santiago Sánchez-Iglesias; Carolina Lorenzo; Alfonso Sevillano-Jiménez; Almudena Sánchez-Martín; María Jesús García-Salgado; María Isidoro-García Journal: Pharmgenomics Pers Med Date: 2021-08-16
Authors: Zane Zeier; Linda L Carpenter; Ned H Kalin; Carolyn I Rodriguez; William M McDonald; Alik S Widge; Charles B Nemeroff Journal: Am J Psychiatry Date: 2018-04-25 Impact factor: 18.112